Flublok® Influenza Vaccine Availability Update: Product to be available to allow vaccination by Thanksgiving

MERIDEN, Conn., Oct. 10, 2013 /PRNewswire/ -- Protein Sciences Corporation announced today that they expect the first doses of Flublok influenza vaccine for the 2013/2014 season to be released in time for vaccinations to occur prior to Thanksgiving. 

According to the Centers for Disease Control and Prevention (CDC), influenza activity typically peaks in January or later.  It takes about two weeks after vaccination for antibodies to develop in the body that protect against influenza virus infection, so it is best that people get vaccinated before then.

FFF Enterprises is the exclusive distributor of Flublok.  To ensure an adequate supply and timely delivery of Flublok, vaccinators should place their orders with FFF as soon as possible.  Orders can be placed by calling (800) 843-7477 or online at www.MyFluVaccine.com.

Manon Cox, President and CEO of Protein Sciences said, "We are pleased to announce the timing of Flublok availability."  She added, "It is important for people to know that the vaccine is coming and will be available in time for people to get protected for the season."

About Protein Sciences and Flublok

Protein Sciences Corporation is a vaccine development and protein production company that is dedicated to saving lives and improving health through the creation of innovative vaccines and biopharmaceu­ticals.  

On January 16, 2013, the U.S. FDA approved Flublok influenza vaccine, coined revolutionary because it is made by making just the active ingredient needed for protection without growing influenza virus.  Flublok is made in a 100% egg-free system using modern cell culture technology.  Flublok is highly pure and does not contain any preservatives (e.g., thimerosal, a mercury derivative), egg proteins, antibiotics or latex.  In addition, it contains 3x the active ingredient in traditional flu vaccines.  The CDC recommends the use of Flublok for all adults 18-49 years old and specifically for those in that age range that have a known or suspected egg allergy, regardless of severity.

Learn more at www.proteinsciences.com and www.Flublok.com.

Important Safety Information
Flublok is approved for people 18-49 years old to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Other side effects may occur and include fatigue, headache and muscle aches.

Flublok should not be administered to anyone with a severe allergic reaction (e.g., anaphylaxis) to any vaccine component.

Tell the doctor if you have ever experienced Guillain-Barre syndrome (severe muscle weakness) within 6 weeks of receipt of a previous dose of influenza vaccine. If you notice any other problems or symptoms following vaccination, please contact your healthcare professional immediately. Vaccination with Flublok may not protect all individuals. 

Please see the complete Package Insert available at www.Flublok.com or call 203-686-0800 for more information.

SOURCE Protein Sciences Corporation